| Absence of the caveolin-1 P132L mutation in cancers of the breast and other organs. | |
| | |
MedLine Citation:
|
PMID: 20581046 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Caveolin-1 belongs to a family of scaffolding proteins, and the P132L point mutation of this gene has been found in up to 16% of all examined breast cancers. Subsequent studies have revealed that the P132L mutation exerts a dominant negative effect through misfolding during caveolin-1 oligomerization. However, this mutation has not been validated in other series of breast cancer samples. Contradictory to the suggested tumor suppressor function, overexpression of caveolin-1 is common in various cancer types. To clarify these inconsistent results, we examined the caveolin-1 mutation in a large series of breast cancer specimens. We first used a standard direct sequencing method and found that none of the 99 breast cancers tested had this mutation. Then we developed a sensitive method for a paraffin section that could detect the mutant allele at a rate of as little as 0.1% among wild-type allele copies. Even when using this sensitive method, none of the 80 estrogen receptor-positive breast tumors had the P132L mutation. Furthermore, 270 cancers in various organs were examined, and no caveolin-1 mutations were detected. These results raise doubt about the presence of the caveolin-1 P132L mutation in breast cancer and other cancer types, and thus further studies are warranted. |
| | |
Authors:
|
Shinya Koike; Yasuhiro Kodera; Akimasa Nakao; Hiroji Iwata; Yasushi Yatabe |
Related Documents
:
|
9988226 - Brca1 gene mutation and loss of heterozygosity on chromosome 17q21 in primary prostate ... 16219936 - Effect of short-term hormone replacement therapy on breast cancer risk reduction after ... 8787076 - Familial breast cancer. 18268356 - Risk-reducing salpingo-oophorectomy for the prevention of brca1- and brca2-associated b... 10802356 - Evaluation of a standard breast tangent technique: a dose-volume analysis of tangential... 14965616 - Il-1 receptor type i expression in breast cancer. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-06-25 |
Journal Detail:
|
Title: The Journal of molecular diagnostics : JMD Volume: 12 ISSN: 1943-7811 ISO Abbreviation: J Mol Diagn Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-08-31 Completed Date: 2011-01-13 Revised Date: 2011-09-13 |
Medline Journal Info:
|
Nlm Unique ID: 100893612 Medline TA: J Mol Diagn Country: United States |
Other Details:
|
Languages: eng Pagination: 712-7 Citation Subset: IM |
Affiliation:
|
Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Chikusa-ku, Nagoya, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Base Sequence Breast Neoplasms / genetics*, pathology Caveolin 1 / genetics* DNA Primers Female Humans Middle Aged Mutation* Paraffin Embedding Polymerase Chain Reaction |
| Chemical | |
Reg. No./Substance:
|
0/Caveolin 1; 0/DNA Primers |
| Comments/Corrections | |
Comment In:
|
J Mol Diagn. 2010 Sep;12(5):562-5
[PMID:
20581045
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Caveolin-1 P132L mutation in human cancers: 1 CAVeat to be voiced.
Next Document: Immiscible phase nucleic acid purification eliminates PCR inhibitors with a single pass of paramagne...